Business Information
The group's principal activity is to develop, market and manufacture medical device products for the treatment of hypervascularized tumors and arteriovenous malformations during embolotherapy. Embolotherapy is a procedure in which embolic materials such as microspheres are injected through a catheter into the blood vessels to inhibit blood flow to tumors and arteriovenous malformations. The group's patented platform technology also has applications in tissue bulking, tissue repair and drug delivery. The products include embosphere(R) microspheres, embogold (TM) microspheres, hepasphere sap (TM) microspheres, temprx (TM) microspheres, etc. In addition to embolotherapic products, the group also sells barium delivery kits and other ancillary products in the European union. Barium kits are purchased from guerbet medical inc and resold for use in gastrointestinal medical testing.
|
|
Name |
Title
|
Email
|
| Gary Saxton | COO, Exec. VP | N/A | | Martin Joyce | CFO, Exec. VP - Finance, Administration | N/A | | Peter Sutcliffe | VP - Manufacturing | N/A | | Alexander Klibanov | Dir. | N/A | | David Southwell | Dir. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 22,891 | (2,324) | | 2005 | 18,484 | (2,801) | | 2004 | 14,158 | (6,841)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
